Glaxosmithkline Consumer Healthcare Ltd. [Merged]
NSE: GSKCONS | BSE: 500676
₹10,732.60
₹496.30
(4.85%)
As on 15-Apr-2020IST
Market cap
₹45,225 Cr
Revenue (TTM)
₹4,984 Cr
P/E Ratio
39.1
P/B Ratio
10.2
Div. Yield
1 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹622 Cr
-
ROE
25.9 %
-
ROCE
39.9 %
-
Industry P/E
22.91
-
EV/EBITDA
24
-
Debt to Equity
0
-
Book Value
₹--
-
EPS
₹274.8
-
Face value
10
-
Shares outstanding
42,055,538
10 Years Aggregate
CFO
₹5,497.78 Cr
EBITDA
₹7,068.81 Cr
Net Profit
₹5,609.81 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Glaxosmithkline [Merged]
| 29.2 | 21.5 | 23.0 | 49.0 | 26.5 | 11.3 | 21.5 |
|
BSE Sensex*
| -11.1 | -4.0 | -9.7 | -8.5 | 7.0 | 8.7 | 11.3 |
|
BSE FMCG#
| -7.1 | 2.0 | -1.4 | -9.9 | 1.8 | 7.6 | 9.1 |
|
Company
|
2019
|
2018
|
2017
|
2016
|
2015
|
2014
|
|---|---|---|---|---|---|---|
|
Glaxosmithkline [Merged]
| 9.7 | 18.0 | 30.7 | -21.4 | 9.9 | 32.6 |
|
BSE Sensex
| 14.4 | 5.9 | 27.9 | 1.9 | -5.0 | 29.9 |
|
BSE FMCG
| -3.6 | 10.5 | 31.5 | 3.3 | 1.4 | 18.3 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Glaxosmithkline [Merged]
|
10,732.6 | 45,225.1 | 4,984.3 | 1,155.8 | 23.9 | 28 | 39.1 | 10.2 |
| 1,023.3 | 6,116.3 | 4,125.2 | 267.0 | 5.5 | 16.8 | 22.9 | 3.8 | |
| 921.8 | 20,506.2 | 9,624.4 | 348.3 | 6.4 | 19.6 | 58.9 | 10.9 | |
| 7.0 | 34.5 | 171.9 | 3.3 | -- | 10.6 | 10.6 | 0.6 | |
| 325.0 | 3,014.0 | 4,526.0 | 151.4 | 4.1 | 13.3 | 20 | 2.7 | |
| 41.1 | 116.7 | 338.8 | 22.4 | 1.9 | 55.1 | 5.2 | 2.0 | |
| 213.3 | 2,696.2 | 3,817.5 | 135.0 | 4.9 | 11.4 | 20 | 2.1 | |
| 434.6 | 460.9 | 326.2 | 15.7 | 11.6 | 11.7 | 29.4 | 3.2 | |
| 4,118.9 | 2,962.2 | 1,359.7 | 122.3 | 11.4 | 16.5 | 24.2 | 4.2 | |
| 37.6 | 76.8 | 167.2 | -7.2 | -3.9 | -10.9 | -- | 1.2 |
Shareholding Pattern
View DetailsNews & Analysis
All News
The Backing of a Resilient Balance Sheet
5 min read•By Jugal Harpalani
2 min read•By Mohammed Ekramul Haque
3 min read•By Mohammed Ekramul Haque
3 min read•By Mohammed Ekramul Haque and Vikas Vardhan
2 min read•By Mohammed Ekramul Haque
1 min read•By Vikas Vardhan
About Glaxosmithkline [Merged]
Manufacture of malted foods including foods for infants and handicapped
-
Incorporated
1958
-
Chairman
P Dwarakanath
-
Managing Director
Navneet Saluja
-
Group
Glaxosmithkline - MNC
-
Headquarters
Nabha, Punjab
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
FAQs for Glaxosmithkline [Merged]
What is the current share price of Glaxosmithkline Consumer Healthcare Ltd [Merged] Today?
The share price of Glaxosmithkline Consumer Healthcare Ltd [Merged] is ₹10,732.60 (NSE) and ₹10,753.65 (BSE) as of 15-Apr-2020 IST. Glaxosmithkline Consumer Healthcare Ltd [Merged] has given a return of 26.53% in the last 3 years.
What is the current PB & PE ratio of Glaxosmithkline Consumer Healthcare Ltd [Merged]?
The P/E ratio of Glaxosmithkline Consumer Healthcare Ltd [Merged] is 39.13 times as on 15-Apr-2020, a 71 premium to its peers’ median range of 22.91 times.
The P/B ratio of Glaxosmithkline Consumer Healthcare Ltd [Merged] is 10.19 times as on 15-Apr-2020, a 167 premium to its peers’ median range of 3.82 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2019
|
30.86
|
7.41
|
|
2018
|
36.61
|
7.36
|
|
2017
|
33.04
|
6.95
|
|
2016
|
36.93
|
9.07
|
|
2015
|
45.40
|
12.54
|
What is the 52 Week High and Low of Glaxosmithkline Consumer Healthcare Ltd [Merged]?
The 52-week high and low of Glaxosmithkline Consumer Healthcare Ltd [Merged] are Rs -- and Rs -- as of 19-May-2026.
What is the market cap of Glaxosmithkline Consumer Healthcare Ltd [Merged]?
Glaxosmithkline Consumer Healthcare Ltd [Merged] has a market capitalisation of ₹ 45,225 Cr as on 15-Apr-2020. As per SEBI classification, it is a company.
Should I invest in Glaxosmithkline Consumer Healthcare Ltd [Merged]?
Before investing in Glaxosmithkline Consumer Healthcare Ltd [Merged], assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.